Sanofi has entered into an agreement with Moderna, under which it will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs.
Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna’s COVID-19 vaccine, starting in September 2021.
“Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity across the industry,” said Paul Hudson, Chief Executive Officer of Sanofi.
“We are one of the few pharmaceutical companies to leverage many industrial partnerships to improve global supply and access to COVID-19 vaccines, while in parallel, also continuing to develop our two COVID-19 vaccine programs.
“I would also like to acknowledge the contributions of the Department of Health and Human Services, and the Biden administration, to facilitate this new partnership.”
This marks Sanofi’s third commitment to provide manufacturing support. Earlier this year, Sanofi announced the company will provide support to BioNTech for 125 million doses for the European Union.